title: Clinical experience with intravenous immunoglobulin and tnf-a inhibitor therapies for recurrent pregnancy loss.
authors.forename: Eric Scott
authors.initials: ES
authors.lastname: Sills
authors.forename: David J
authors.initials: DJ
authors.lastname: Walsh
authors.forename: Lyuda V
authors.initials: LV
authors.lastname: Shkrobot
authors.forename: Gianpiero D
authors.initials: GD
authors.lastname: Palermo
authors.forename: Anthony Ph
authors.initials: AP
authors.lastname: Walsh
mesh_terms: D000328:Adult; D002585:Cesarean Section; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept